Ameriflex Group Inc. acquired a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,380 shares of the pharmacy operator's stock, valued at approximately $197,000.
Other hedge funds also recently made changes to their positions in the company. Stonebridge Financial Group LLC bought a new position in CVS Health in the fourth quarter valued at $28,000. Hopwood Financial Services Inc. bought a new position in CVS Health during the fourth quarter worth $29,000. McIlrath & Eck LLC boosted its holdings in shares of CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after buying an additional 174 shares during the period. Financial Perspectives Inc boosted its holdings in shares of CVS Health by 137.5% during the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after acquiring an additional 466 shares during the period. Finally, Compass Planning Associates Inc bought a new stake in shares of CVS Health in the fourth quarter valued at about $37,000. 80.66% of the stock is owned by institutional investors.
CVS Health Price Performance
NYSE:CVS traded up $1.21 during trading hours on Friday, hitting $63.99. The stock had a trading volume of 13,306,917 shares, compared to its average volume of 11,213,338. The firm has a market capitalization of $80.95 billion, a price-to-earnings ratio of 17.48, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The company has a 50 day simple moving average of $65.62 and a two-hundred day simple moving average of $59.64. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $1.31 EPS. Research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.
CVS Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.16%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is currently 63.48%.
Insiders Place Their Bets
In other news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.22% of the company's stock.
Analyst Upgrades and Downgrades
CVS has been the subject of a number of recent analyst reports. Leerink Partners upgraded CVS Health from a "market perform" rating to an "outperform" rating and upped their target price for the company from $55.00 to $75.00 in a research report on Thursday, February 13th. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research report on Friday, March 21st. Mizuho raised their price objective on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Argus set a $77.00 price target on shares of CVS Health in a research note on Tuesday, February 18th. Finally, Wolfe Research upped their target price on shares of CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $74.94.
Get Our Latest Analysis on CVS Health
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
